This cytostatic effect of PI3K/mTOR inhibition has been previously described for both GBM and other tumor entities [28, 48, 52, 53] and is often cited as caveat for the use of PI3K inhibitors in combination therapy with classical chemotherapy. Here, MTOR is linked to neoplasm.